CEMP Cempra Inc.

3.15
+0.05  (2%)
Previous Close 3.10
Open 3.15
Price To book 1.09
Market Cap 165404235
Shares 52,509,281
Volume 1,308,760
Short Ratio 5.45
Av. Daily Volume 702,819

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 data due by the end of 2017.
Taksta - Fusidic acid
Refractory infections in bones and joints
CRL announced December 29, 2016. Further trials required.
Solithera - intravenous
Community-acquired bacterial pneumonia (CABP)
CRL announced December 29, 2016. Further trials required.
Solithera - oral
Community-acquired bacterial pneumonia (CABP)
Phase 2 interim data released September 30, 2016. Noted February 28, 2017 that development has been suspended due to lack of efficacy.
Solithromycin
NASH
Phase 3 initiated August 2014. Enrollment completed December 2015 but decided to increase enrollment. Noted January 9, 2017 that extension enrollment has been slower than envisaged. Finally noted February 28, 2017 that data did not demonstrate non-inferiority (NI) to standard of care.
Solithromycin
Uncomplicated urogenital gonococcal infections
Phase 3 data released February 24, 2017 - endpoints met. Second Phase 3 trial to be initiated.
Taksta - Fusidic acid
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 2 trial discontinued - noted January 9, 2017.
Solithromycin
COPD